Cargando…

Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes

The identification of minimal residual disease is the primary diagnostic finding which predicts relapse in patients treated for acute myeloid leukemia. Ultrasensitive detection of minimal residual disease would enable better patient risk stratification and could open opportunities for early therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Waalkes, Adam, Penewit, Kelsi, Wood, Brent L., Wu, David, Salipante, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685235/
https://www.ncbi.nlm.nih.gov/pubmed/28572161
http://dx.doi.org/10.3324/haematol.2017.169136
_version_ 1783278603603017728
author Waalkes, Adam
Penewit, Kelsi
Wood, Brent L.
Wu, David
Salipante, Stephen J.
author_facet Waalkes, Adam
Penewit, Kelsi
Wood, Brent L.
Wu, David
Salipante, Stephen J.
author_sort Waalkes, Adam
collection PubMed
description The identification of minimal residual disease is the primary diagnostic finding which predicts relapse in patients treated for acute myeloid leukemia. Ultrasensitive detection of minimal residual disease would enable better patient risk stratification and could open opportunities for early therapeutic intervention. Herein we apply single molecule molecular inversion probe capture, a technology combining multiplexed targeted sequencing with error correction schemes based on molecular barcoding, in order to detect mutations identifying minimal residual disease with ultrasensitive and quantitative precision. We designed a single molecule molecular inversion probe capture panel spanning >50 kb and targeting 32 factors relevant to acute myeloid leukemia pathogenesis. We demonstrate linearity and quantitative precision over 100-fold relative abundance of mutant cells (1 in 100 to 1 in 1,500), with estimated error rates approaching 1 in 1,200 base pairs sequenced and maximum theoretical limits of detection exceeding 1 in 60,000 mutant alleles. In 3 of 4 longitudinally collected specimens from patients with acute myeloid leukemia, we find that single molecule molecular inversion probe capture detects somatic mutations identifying minimal residual disease at substantially earlier time points and with greater sensitivity than clinical diagnostic approaches used as current standard of care (flow cytometry and conventional molecular diagnosis), and identifies persisting neoplastic cells during clinical remission. In 2 patients, single molecule molecular inversion probe capture detected heterogeneous, subclonal acute myeloid leukemia populations carrying distinct mutational signatures. Single molecule molecular inversion probe technology uniquely couples scalable target enrichment with sequence read error correction, providing an integrated, ultrasensitive approach for detecting minimal residual disease identifying mutations.
format Online
Article
Text
id pubmed-5685235
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ferrata Storti Foundation
record_format MEDLINE/PubMed
spelling pubmed-56852352017-11-21 Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes Waalkes, Adam Penewit, Kelsi Wood, Brent L. Wu, David Salipante, Stephen J. Haematologica Article The identification of minimal residual disease is the primary diagnostic finding which predicts relapse in patients treated for acute myeloid leukemia. Ultrasensitive detection of minimal residual disease would enable better patient risk stratification and could open opportunities for early therapeutic intervention. Herein we apply single molecule molecular inversion probe capture, a technology combining multiplexed targeted sequencing with error correction schemes based on molecular barcoding, in order to detect mutations identifying minimal residual disease with ultrasensitive and quantitative precision. We designed a single molecule molecular inversion probe capture panel spanning >50 kb and targeting 32 factors relevant to acute myeloid leukemia pathogenesis. We demonstrate linearity and quantitative precision over 100-fold relative abundance of mutant cells (1 in 100 to 1 in 1,500), with estimated error rates approaching 1 in 1,200 base pairs sequenced and maximum theoretical limits of detection exceeding 1 in 60,000 mutant alleles. In 3 of 4 longitudinally collected specimens from patients with acute myeloid leukemia, we find that single molecule molecular inversion probe capture detects somatic mutations identifying minimal residual disease at substantially earlier time points and with greater sensitivity than clinical diagnostic approaches used as current standard of care (flow cytometry and conventional molecular diagnosis), and identifies persisting neoplastic cells during clinical remission. In 2 patients, single molecule molecular inversion probe capture detected heterogeneous, subclonal acute myeloid leukemia populations carrying distinct mutational signatures. Single molecule molecular inversion probe technology uniquely couples scalable target enrichment with sequence read error correction, providing an integrated, ultrasensitive approach for detecting minimal residual disease identifying mutations. Ferrata Storti Foundation 2017-09 /pmc/articles/PMC5685235/ /pubmed/28572161 http://dx.doi.org/10.3324/haematol.2017.169136 Text en Copyright© 2017 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.
spellingShingle Article
Waalkes, Adam
Penewit, Kelsi
Wood, Brent L.
Wu, David
Salipante, Stephen J.
Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes
title Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes
title_full Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes
title_fullStr Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes
title_full_unstemmed Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes
title_short Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes
title_sort ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685235/
https://www.ncbi.nlm.nih.gov/pubmed/28572161
http://dx.doi.org/10.3324/haematol.2017.169136
work_keys_str_mv AT waalkesadam ultrasensitivedetectionofacutemyeloidleukemiaminimalresidualdiseaseusingsinglemoleculemolecularinversionprobes
AT penewitkelsi ultrasensitivedetectionofacutemyeloidleukemiaminimalresidualdiseaseusingsinglemoleculemolecularinversionprobes
AT woodbrentl ultrasensitivedetectionofacutemyeloidleukemiaminimalresidualdiseaseusingsinglemoleculemolecularinversionprobes
AT wudavid ultrasensitivedetectionofacutemyeloidleukemiaminimalresidualdiseaseusingsinglemoleculemolecularinversionprobes
AT salipantestephenj ultrasensitivedetectionofacutemyeloidleukemiaminimalresidualdiseaseusingsinglemoleculemolecularinversionprobes